Abstract: Journal Pre-proof Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phaseRunning title: Survival benefits of COVID-19 oral antiviral drugs Eric Yuk Fai Wan Boyuan Wang Sukriti Mathur Cheyenne I Ying Chan Vincent Ka Chun Yan Francisco Tsz Tsun Lai Celine Sze Ling Chui Xue Li Carlos King Ho Wong Philip Hei Li Chak Sing Lau Ian Chi Kei Wong Esther Wai Yin Chan PII: S0163-4453(23)00117-2 DOI: https://doi.org/10.1016/j.jinf.2023.02.029 Reference: YJINF5894 To appear in: Journal of Infection Accepted date: 18 Please cite this article as: Eric Yuk Fai Wan, Boyuan Wang, Sukriti Mathur, Cheyenne I Ying Chan, Vincent Ka Chun Yan, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Xue Li, Carlos King Ho Wong, Philip Hei Li, Chak Sing Lau, Ian Chi Kei Wong and Esther Wai Yin Chan, Molnupiravir and nirmatrelvirritonavir reduce mortality risk during post-acute COVID-19 phaseRunning title: Survival benefits of COVID-19 oral antiviral drugs, Journal of Infection, () doi:https://doi.org/10.1016/j.jinf.2023.02.029 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © Published by Elsevier. Title: Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase Authors: Eric Yuk Fai Wan, PhD1,2,3†; Boyuan Wang, MPH3†, Sukriti Mathur, BSc3†, Cheyenne I Ying Chan, MPsyMed3, Vincent Ka Chun Yan, BPharm1; Francisco Tsz Tsun Lai, PhD1,2; Celine Sze Ling Chui, PhD2,4,5; Xue Li, PhD1,2,6; Carlos King Ho Wong, PhD1,2,3; Philip oo f Hei Li, MBBS6; Chak Sing Lau, MD6; Ian Chi Kei Wong, PhD1,2,7,8*, Esther Wai Yin Chan, PhD1,2,7,9* Centre for Safe Medication Practice and research, Department of Pharmacology and e- 1 pr Affiliations: Pr Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, 3 ur n Hong Kong China al 2 Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Jo 4 Kong China 5 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China 6 Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong China 7 Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China 1 8 Aston Pharmacy School, Aston University, Birmingham, B4 7ET, UK 9 The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China † Co-first authors and contributed equally oo Running title: Survival benefits of COVID-19 oral antiviral drugs f * Co-Corresponding authors pr Correspondence Dr Esther W. Chan, PhD e- Associate Professor, Department of Pharmacology and Pharmacy Pr Research Lead, Centre for Safe..